Mayo Clinic Laboratories > Neurology > Autoimmune > Necrotizing autoimmune myopathy

Necrotizing autoimmune myopathy

A targeted and accelerated approach to diagnosis

Immune-mediated necrotizing myopathy (IMNM), also called necrotizing autoimmune myopathy (NAM), is a rare but serious muscle disease strongly associated with autoantibodies to either signal recognition protein (SRP-IgG) or 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR-IgG). Our testing can provide earlier identification and treatment initiation in patients with IMNM, which is critical to preventing further harm.

2/3

2/3 of IMNM patients will be seropositive for HMGCR-IgG or SRP-IgG

Necrotizing autoimmune myopathy Test menu

Necrotizing autoimmune myopathy Necrotizing autoimmune myopathy

Necrotizing autoimmune myopathy

Key testing

Advantages

  • A single evaluation with the two most pertinent antibodies associated with IMNM: HMGCR-IgG and SRP-IgG. The combination of both antibodies maximizes clinical sensitivity for diagnosing patients with this disease.
  • Detection of SRP-IgG using a sensitive immunofluorescence-based assay and then confirming by a second immunoblot technology.
  • Antibodies are tested in parallel, providing results in approximately one week.
IMNM calculator Assess probability of necrotizing myopathy for your patients
NOTE: A thorough understanding of a patient’s history, along with clinical examination and laboratory testing, are still needed for a clinic-sero-pathological diagnosis of IMNM.
Learn more The study validating the effectiveness of diagnostic modeling tools like our online calculator

Highlights

Improved Diagnosis of Necrotizing Autoimmune Myopathy by Combinatorial Immune Assays

This “Specialty Testing” webinar will discuss the diagnosis, pathological understanding, and current best treatment options for necrotizing autoimmune myopathy.

Learn more
Necrotizing Autoimmune Myopathy [Test in Focus]

Necrotizing autoimmune myopathy (NAM) is a serious but rare muscle disease strongly associated with autoantibodies to either the protein signal recognition particle (SRP) or the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). NAM typically manifests with subacute proximal limb muscle weakness and persistently elevated serum creatine kinase (CK) concentrations, but slower onsets can occur and complicate diagnosis.

Learn more
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

Are you a patient? Click here.

(BETA) Choose a language to view this content in:
About the translation.